Background: Glucagon-like peptide-1 (GLP-1) receptors were identified in both acinar and ductal cells of pancreas. Animal studies suggested an association of GLP-1 agonists use and pancreatic premalignant changes. Randomized controlled trials (RCT) in humans did not report this association, but it may be due to lack of sample power of individual studies.

Aim: To access if GLP-1 agonists are associated with pancreatic cancer.

Methods: Systematic review and meta-analysis of randomized trials with GLP-1 agonists as intervention. Trials that lasted more than 48 weeks were included. Trial sequential analysis (TSA) was performed to access if available information is enough to discard this association.

Results: Twelve trials met study criteria, including 36, 397 patients. GLP-1 analogs did not increase the risk for pancreatic cancer when compared to other treatments (OR 1.14; 95% CI 0.68 to 1.92; I2 0%)(Figure 1). TSA confirmed that enough patients were randomized to exclude this association, and a number needed to harm (NNH) higher than 1000 was reached (Figure 2).

Conclusion: There is enough information to discard the concern regarding GLP-1 agonists and pancreatic cancer.


L.C. Pinto: None. D.V. Rados: None. M.R. Falcetta: None. C.B. Leitao: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at